Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis

Fadi Shehadeh, Markos Kalligeros, Katrina Byrd, Douglas Shemin, Eleftherios Mylonakis, Paul Martin & Erika M. C. D’Agata

Hepatitis C virus (HCV) infection among maintenance hemodialysis patients is implicated in increased morbidity and mortality compared to uninfected patients. Sofosbuvir (SOF)-based regimens may not be optimal among patients requiring hemodialysis. Several studies, however, provide evidence that use of SOF among HCV-positive patients with renal impairment, is effective and safe. We searched PubMed and Embase to identify studies reporting the efficacy and safety of SOF-based regimens for the treatment of HCV-positive patients on maintenance hemodialysis and performed a random effects meta-analysis. The overall pooled estimate of the efficacy of SOF-based therapy was 95% (95% CI 91–98%). The efficacy of the SOF-based regimen was 92% (95% CI 80–99%), 98% (95% CI 96–100%), and 100% (95% CI 95–100%) for the following doses: 400 mg on alternate days, 400 mg daily, and 200 mg daily, respectively. The most frequent adverse event was fatigue with a pooled prevalence of 16% (95% CI 5–29%), followed by anemia 15% (95% CI 3–31%), and nausea or vomiting 14% (95% CI 4–27%). Anemia was more prevalent in treatment regimens containing ribavirin (46%, 95% CI 33–59%) compared to ribavirin-free regimens (3%, 95% CI 0–9%). This study suggests that SOF-based regimens in the treatment of HCV infection among hemodialysis patients are both effective and safe.

Patients requiring hemodialysis are at an increased risk of acquiring hepatitis C virus (HCV). Approximately 5% of patients on hemodialysis are diagnosed with HCV, compared to 1% in the United States population and, among hemodialysis patients, HCV infection is associated with poor outcomes with substantially higher rates of hepatic-related mortality and hospitalizations, and lower health-related quality of life scores, compared to HCV negative hemodialysis patients.

National guidelines for the treatment of HCV infection among hemodialysis patients recommend several direct-acting antivirals (DAA). Sofosbuvir (SOF)-based regimens are not recommended for patients requiring hemodialysis since renal clearance of SOF is the major elimination pathway, although since the recent U.S. Federal Drug Administration change in label, removing restrictions on its use in renal impairment, this will undoubtedly change. Nevertheless, clinical studies provide evidence that use of SOF, among HCV positive patients with renal impairment, is effective and safe. Data focusing only on patients requiring maintenance hemodialysis are limited. Thus, we performed a systematic review and meta-analysis to quantify the efficacy and safety of SOF-based regimens among the subset of patients with severe renal impairment that required maintenance hemodialysis.

1Infectious Diseases Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital, 593 Eddy Street, POB 328, Providence, RI, USA.
2Kidney Disease Division, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, USA.
3Division of Digestive Health and Liver Disease, Miller School of Medicine, University of Miami, Miami, FL, USA. *email: fanti_sechante@brown.edu
Results

Our systematic search yielded 777 studies of which 60 were eligible for full text review. A total of 20 studies were in accordance with our eligibility criteria and were included in the meta-analysis (Table 1). The selection process is detailed in Fig. 1.

The included studies were published from 2015 to 2020 and contained extractable data on 514 patients enrolled from 2014 to 2016. Four studies were retrospective and 16 were prospective. Nine of the studies were conducted in India, 2 in the USA, 2 in Pakistan, 2 in China, 1 in France, 7 in other countries. Table 1 provides a summary of study and patient characteristics.

Table 1. Summary of study and patient characteristics. NR Not reported, GT genotype, SVR12 sustained virologic response 12 weeks after treatment, AD alternate day, RBV ribavirin, SMV simeprevir, LDV ledipasvir, DCV daclatasvir, VPV velpatasvir.

| Study          | Study period | Type of study | Country     | Population (N) | Age (mean) | Male (%) | Genotype (%) | Combination drugs | Sofosbuvir dose | SVR12 N (%) |
|---------------|--------------|---------------|-------------|----------------|------------|----------|--------------|------------------|----------------|-----------|
| Agarwal et al. | 2015–2016    | Prospective   | India       | 62             | 33.8       | 66.1     | GT-1: 65, GT-2: 2, GT-3: 29, GT-4: 3, GT-6: 2 | RBV, DCV      | 400 mg AD, 400 mg daily | 59 (95%) |
| Akhil et al.   | 2015–2016    | Retrospective | India       | 22             | 49.76      | 68.2     | GT-1: 64, GT-3: 27, GT-4: 9 | RBV, DCV      | 400 mg daily | 16 (73%) |
| Bhamidimarri et al. | 2014–2015 | Prospective   | USA          | 10             | 59.7       | 91.7     | GT-1a: 67, GT-1b: 33 | SMV            | 200 mg daily, 400 mg AD | 10 (83%) |
| Choudhary et al. | 2015–2016 | Prospective   | India        | 2              | 56.5       | 100      | GT-1: 50, GT-3: 50, DCV | 400 mg AD      | 2 (100%) |
| Desnoyer et al. | 2014–2015    | Prospective   | France       | 12             | 54.4       | 83.3     | GT-1: 92, GT-2: 8 | SMV, DCV, LDV, RBV | 400 mg daily, 400 mg 3 times/week | 10 (83%) |
| Gupta et al.   | 2015–2016    | Prospective   | India        | 7              | 48.4       | 71.4     | GT-1: 57, GT-3: 43 | DCV, RBV     | 200 mg daily | 6 (86%) |
| He et al.     | 2016         | Prospective   | China        | 33             | 52.8       | 72.7     | GT-1a: 21, GT-2a: 73, GT-1b + 2a: 6 | DCV           | 200 mg daily | 33 (100%) |
| Mehta et al.  | 2016         | Prospective   | India        | 38             | 49.5       | 68.4     | GT-1a: 42, GT-1b: 58 | LDV, DCV    | 400 mg daily, 400 mg AD      | 33 (87%) |
| Sperl et al.  | 2015–2016    | Retrospective | Czech Republic | 6             | 39         | 100      | GT-3: 100 | DCV               | 200 mg daily | 6 (100%) |
| Surendra et al. | 2015        | Prospective   | India        | 21             | 44         | 61.9     | GT-1a: 57, GT-1b: 33 | LDV           | 400 mg AD | 19 (90%) |
| Singh et al.  | 2014–2015    | Prospective   | USA          | 8              | 56.8       | 25       | GT-1a: 38, GT-1b: 38, GT-3: 13, GT-4: 13 | SMV, LDV     | 400 mg daily | 7 (88%) |
| Borgia et al. | 2017–2018    | Prospective   | Canada, UK, Spain, Israel, New Zealand, Australia | 59 | 60 | 35 | GT-1a: 25, GT-1b: 19, GT-2: 12, GT-3: 32, GT-4: 7, GT-6: 3 | VPV           | 400 mg daily | 56 (95%) |
| See et al.    | 2017–2018    | Retrospective | Korea        | 9              | 59.9       | 66.7     | GT-2: 100 | RBV               | 400 mg daily | 9 (100%) |
| Lin et al.    | 2017         | Prospective   | China        | 7              | 53         | 71.4     | GT-1a: 57, GT-2a: 29, GT-6: 14 | DCV, LDV     | 400 mg daily | 6 (86%) |
| Debnath et al. | 2017–2018    | Prospective   | India        | 18             | 39.4       | 77.8%    | GT-1: 66.7, GT-2: 5.5, GT-3: 22.3, GT-5: 5.5 | DCV, LDV     | 400 mg daily | 18 (100%) |
| Singh et al.  | 2015–2017    | Prospective   | India        | 39             | 39.6       | 83%      | GT-1: 68, GT-3: 28, GT-4: 4.3 | DCV, LDV     | 400 mg daily | 37 (95%) |
| Mandiwani et al. | 2016–2018 | Prospective   | Pakistan     | 73             | 31.9       | 72.9%    | GT-1: 50.3, GT-2: 0.7, GT-3: 42.9, GT-4: 1.48 | DCV, RBV     | 400 mg daily | 70 (96%) |
| Hussein et al. | 2017         | Prospective   | Iraq         | 19             | 54.8       | 63%      | GT-1a: 100 | DCV, LDV       | 200 mg daily, 400 mg daily | 19 (100%) |
| Gaur et al.   | 2017–2018    | Retrospective | India        | 31             | 39.8       | 77.5%    | GT-1: 67.7, GT-3: 32.2 | VPV           | 400 mg daily | 30 (97%) |
| Cheema et al. | 2017–2018    | Prospective   | Pakistan     | 36             | 47.22 Group 1, 53.89 Group 2 | 61.1% | GT-1: 33.3, GT-2: 2.8, GT-3: 63.9 | DCV           | 400 mg daily (Group 1), 400 mg 3 times/week (Group 2) | 29 (80%) |
Czech Republic, Korea, Iraq, and 1 enrolled patients from multiple countries. All studies received more than five stars in the Newcastle-Ottawa Scale and no study was excluded due to quality concerns.

The overall pooled estimate of the efficacy of SOF-based therapy among HCV positive patients on maintenance hemodialysis was 95% (95% CI 91–98%), ranging from 73 to 100% (Fig. 2). There was moderate heterogeneity among studies (I² = 40.3%, p < 0.05). A meta-regression analysis did not demonstrate any evidence that the differences in gender, age, HCV genotypes, or type of SOF-based regimens among studies were correlated with the between study heterogeneity (p = 0.97). Egger’s test for publication bias yielded insignificant results (bias = −0.76, p = 0.46), suggesting absence of small-study effects.

A total of 19 studies reported extractable data on the SOF dose and the other DAA included in the treatment regimen. In nine studies, the same treatment regimen was used for all study participants. Six studies partitioned the study participants into subgroups and followed a different treatment strategy for each subgroup. Each treatment strategy was considered as a separate observation in our analysis and was included separately in its respective subgroup.

The efficacy from the studies that reported extractable data on the treatment regimen used varied from 50 to 100% (Fig. 3). Studies were sub-grouped based on the SOF-dose administered. The pooled efficacy of the sofosbuvir regimen was 92% (95% CI 80–99%) in patients administered a 400 mg alternate day dose, 98% (95% CI 96–100%) in those administered a 400 mg daily dose, and 100% (95% CI 95–100%) in patients administered a 200 mg daily dose (Fig. 3). A sub-group analysis was not performed for the various other DAA used in the treatment regimens, due to the large variability of DAA used. Ribavirin was used in 6 studies, simeprevir in 3, ledipasvir in 8, daclatasvir in 9, and velpatasvir in 2 studies.

Six studies included extractable data on the efficacy of SOF-based therapy in patients with cirrhosis. The pooled estimate of the efficacy of SOF-based therapy among HCV positive patients on maintenance hemodialysis with cirrhosis was 97% (95% CI 84–100%), ranging from 67 to 100% (Supplementary Fig. 1).

A total of 16 studies reported extractable data on adverse events. The most commonly reported adverse events were anemia (10 studies), headache (8 studies), fatigue (6 studies), nausea or vomiting (5 studies), insomnia (5 studies), rash or itching (4 studies), and dizziness (4 studies). The most frequent adverse event was fatigue with an overall pooled prevalence of 16% (95% CI 5–29%) (Fig. 4). Anemia ranged from 0 to 56%, with an overall pooled prevalence of 15% (95% CI 3–31%) (Fig. 5). Anemia was more prevalent in treatment regimens containing ribavirin (46%, 95% CI 33–59%) compared to regimens that did not contain ribavirin (3%, 95% CI 0–9%). The overall pooled prevalence of headache was 7% (95% CI 3–13%), nausea or vomiting 14% (95% CI 4–27%), insomnia 3% (95% CI 0–8%), rash or itching 7% (95% CI 0–18%). Two studies reported drug discontinuation due to adverse events.

Cheema et al. reported a treatment related serious adverse event (drug induced rash) in 1 patient, and Gupta et al. reported that 1 patient developed recurrent hypoglycemia which improved after stopping therapy.
Discussion

A systematic review and meta-analysis was conducted to determine the safety and efficacy of SOF-based regimens in the treatment of HCV infection among patients requiring maintenance hemodialysis. Among the 934 studies that were identified in our database search, 20 studies met our inclusion criteria. Overall, the pooled estimate of efficacy, based on SVR12, was 95%, ranging from 73 to 100%. Using meta-regression analyses, no statistically significant differences were identified for patient demographics, use of different types of DAA in addition to SOF, or HCV genotypes. Among the studies that reported the dose of SOF, no statistically significant differences in SVR12 were noted with pooled estimates of 92%, 98%, and 100% for SOF doses of 400 mg on alternate days, 400 mg daily, and 200 mg daily, respectively.

Among the studies that reported adverse events, anemia was the most common with a pooled prevalence of 15%. A total of 10 (50%) studies reported anemia as an adverse event. Among these, 6 (60%) included ribavirin in the SOF-based regimens. Since ribavirin frequently causes anemia, a subset analysis was performed to compare rates of anemia among ribavirin and ribavirin-free regimens. The prevalence of anemia was significantly higher in regimens containing ribavirin (46%) compared to ribavirin-free regimens (3%). Other adverse events identified in this meta-analysis, included fatigue, rash or itching, headaches, insomnia, and nausea or vomiting with pooled estimates of 16%, 7%, 7%, 3%, and 14%, respectively.

Several large-scale studies evaluated the efficacy and safety among patients with HCV infection and severe renal impairment, treated with SOF-based regimens. A longitudinal prospective study by Saxena et al. compared outcomes of HCV infection between 1716 pts with estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m² to 73 patients with an eGFR ≤ 45, of which five were on hemodialysis. Patients were treated with SOF 400 mg daily and 60% also received ribavirin. Among patients with eGFR ≤ 45, SVR12 was achieved among 83% of patients. Reported rates of adverse events, in this subset of patients, were similar to our study, with anemia, fatigue, and headaches occurring in 30%, 30% and 14% of patients, respectively. Rash or itching was not
reported. A meta-analysis by Li et al. evaluated studies of SOF-based regimens among HCV positive patients with stage 4 or 5 chronic kidney disease (GFR < 30 mL/min/1.73 m²). Their outcome of efficacy combined SVR at 12 and 24 weeks. Twenty-one studies were included, with a total of 717 HCV infected patients, of whom 306 (58.4%) were on either hemodialysis or peritoneal dialysis. Doses of SOF varied and a subset also received ribavirin. Among patients requiring dialysis, the pooled SVR12/24 was 95%. Rates of anemia, fatigue, headache, rash or itching were not reported. Lastly, in November 2019, the U.S. Food and Drug Administration (FDA) updated the prescribing of several SOF-based regimens, which now states that no dosage adjustment is required for patients with any degree of renal impairment. In the updated labeling report for sofosbuvir/velpatasvir, for example, the FDA reported an overall SVR of 95% among 59 patients requiring hemodialysis or peritoneal dialysis. Adverse events were not provided. Our findings support the notion that the use of Sofosbuvir based regimens in patients receiving hemodialysis is both safe and effective. In our analysis, hemodialysis did not

Figure 3. Forest plot of included studies sub-grouped by sofosbuvir dose. Individual and combined estimates of the efficacy of SOF-based therapy for each sub-group with 95% confidence intervals. ES effect size (efficacy).
seem to be an unfavorable factor, in terms of safety and efficacy, when compared to other meta-analyses which included Hepatitis C patients without renal disease32,33.

There are several limitations that warrant discussion. First, substantial heterogeneity was found among studies, which we addressed by using a random effects model instead of a fixed effects model. Furthermore, meta-regression analysis of specific variables, including patient demographics, HCV genotype and SOF dose did not identify any statistically significant differences. Second, although some publications reported lower SVR rates based on different SOF-based regimens, a subset analyses of types of SOF-based regimens and a comparison of NS5A and NS3 protease inhibitor regimens could not be performed due to the small number of studies in each group. Future studies will need to compare differences in efficacy and safety among SOF-based regimens using different DAA. Third, efficacy by specific HCV genotype could not be determined, again due to the small number of patients and that data pertaining to specific genotypes and outcomes were not extractable.

In conclusion, our findings support that the use of SOF-based regimens in the treatment of HCV infection among patients requiring hemodialysis is both safe and effective. Future randomized controlled studies are needed to confirm these results and to evaluate the optimal SOF-based treatment regimen.

Methods

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA)34 and has been registered in PROSPERO (CRD42018116632, https://www.crd.york.ac.uk/PROSPERO).

Search strategy. A systematic search of Pubmed and Embase databases was performed to identify studies reporting the efficacy and safety of SOF-based regimens for the treatment of HCV positive patients on maintenance hemodialysis. The following search term was used: (end stage renal disease OR renal replacement therapy OR chronic kidney failure OR severe renal impairment OR chronic kidney disease OR hemodialysis) AND (sofosbuvir). Results were limited to the English language and publication dates until May 22, 2020. Additionally, references of systematic reviews focusing on HCV treatment were reviewed manually.

Eligibility criteria and study selection. Two reviewers (KB and EMCD) independently screened and evaluated the studies that were potentially eligible for inclusion with discrepancies were resolved either between the two reviewers or a third party (FS), if consensus could not be reached. Studies were included if they reported extractable data on the number of maintenance hemodialysis patients that completed a SOF-based regimen and had values for a sustained virologic response 12 weeks after the completion of treatment (SVR12). Our primary outcome of interest was the efficacy of SOF-based therapy in HCV positive patients on maintenance hemodialysis. Regimen efficacy was defined as the proportion of patients that had SVR12. As a secondary outcome of interest, we evaluated the safety of SOF-based regimens, by quantifying the proportion of patients with reported adverse events.

Studies that reported only aggregate data on patients, regardless of their dependency on hemodialysis, were excluded as were opinion pieces and conference abstracts. Studies that focused on patients < 18 years old, HIV positive patients or transplant recipients were also excluded. SOF-based regimens that included pegylated interferon were also excluded.

### Table 2. Adverse events reported for sofosbuvir-based regimens. NR Not reported.

| Study                  | Number of patients | Anemia (%) | Fatigue (%) | Rash or itching (%) | Headache (%) | Nausea/vomiting (%) | Insomnia (%) |
|------------------------|--------------------|------------|-------------|---------------------|--------------|---------------------|--------------|
| Agarwal et al.14       | 62                 | 23 (37%)   | NR          | NR                  | NR           | NR                  | NR           |
| Akhil et al.15         | 22                 | 9 (41%)    | NR          | NR                  | NR           | NR                  | NR           |
| Choudhary et al.16      | 7                  | 3 (43%)    | 2           | NR                  | NR           | NR                  | NR           |
| Desnoyer et al.17       | 12                 | 3 (25%)    | 2 (17%)     | 1 (8%)              | 2 (17%)      | NR                  | NR           |
| Gupta et al.18         | 7                  | 1 (14%)    | NR          | NR                  | NR           | NR                  | NR           |
| He et al.19            | 33                 | NR         | 13 (39%)    | NR                  | 13           | 1                   |
| Sperl et al.20         | 6                  | 0          | NR          | NR                  | NR           | NR                  | NR           |
| Surendra et al.21       | 21                 | NR         | 0           | NR                  | 1 (5%)       | 0                   | 0            |
| Singh T. et al.22       | 8                  | 1 (13%)    | NR          | 1 (13%)             | 1            | 1                   |
| Borgia et al.23         | 59                 | 4 (7%)     | 8           | NR                  | 10           | 8                   | 1            |
| Soo et al.24           | 9                  | 5 (56%)    | 2           | 2                   | NR           | NR                  | 1            |
| Lin et al.25           | 7                  | NR         | NR          | NR                  | 1            | NR                  | NR           |
| Debmath et al.26        | 18                 | 0 (0%)     | 2           | NR                  | 1            | 1                   | 4            |
| Singh A. et al.27       | 39                 | 0 (0%)     | NR          | 1                   | 1            | 1                   | 4            |
| Mandhwani et al.28      | 73                 | 28 (%)     | NR          | NR                  | NR           | NR                  | NR           |
| Gaur et al.29           | 31                 | 2 (38%)    | NR          | NR                  | 1            | NR                  | NR           |
Data extraction and quality assessment. For each included study, we extracted the following information: study period, country, type of study, age, gender, HCV genotype, number of patients on a SOF-based therapy, other DAA used in treatment regimen, SOF dose, number of patients who had SVR12, and adverse events. Data extraction was performed by FS and checked for accuracy by EMCD.

We assessed the quality of the eligible studies using the Newcastle–Ottawa Scale. A maximum of six stars could be assigned to each study, as the parameters "selection of the non-exposed cohort" and "comparability between cohorts" were not applicable to our analysis. High quality studies were defined as studies that received ≥ 5 stars (Supplementary Table 1).

Data synthesis and analysis. We performed a random effects meta-analysis to estimate the pooled efficacy of SOF-based therapy in HCV positive patients on dialysis, using the DerSimonian and Laird approach. The Freeman Tukey double arcsine transformation was used to stabilize the variances. We selected a random

| Study               | ES (95% CI) | % Weight |
|---------------------|-------------|----------|
| Fatigue             |             |          |
| Borgia et al. (2019)| 0.14 (0.07, 0.25) | 4.61     |
| Choudhary et al. (2017)| 0.29 (0.06, 0.84) | 1.88     |
| Debnath et al. (2019)| 0.11 (0.03, 0.33) | 3.15     |
| Desnoyer et al. (2016)| 0.17 (0.05, 0.45) | 2.58     |
| Ho et al. (2017)    | 0.39 (0.25, 0.56) | 3.97     |
| Seo et al. (2020)   | 0.22 (0.06, 0.55) | 2.19     |
| Surendra et al. (2018)| 0.00 (0.00, 0.15) | 3.36     |
| Subtotal (I^2 = 68.9%, p = 0.00) | 0.16 (0.05, 0.29) | 21.73     |
| Pruritus            |             |          |
| Desnoyer et al. (2016)| 0.08 (0.01, 0.35) | 2.58     |
| Seo et al. (2020)   | 0.22 (0.06, 0.55) | 2.19     |
| Singh A. et al. (2018)| 0.03 (0.00, 0.13) | 4.17     |
| Singh T. et al. (2016)| 0.13 (0.02, 0.47) | 2.64     |
| Subtotal (I^2 = 28.9%, p = 0.24) | 0.07 (0.00, 0.18) | 10.97     |
| Headache            |             |          |
| Borgia et al. (2019)| 0.17 (0.09, 0.28) | 4.61     |
| Debnath et al. (2019)| 0.06 (0.01, 0.26) | 3.15     |
| Desnoyer et al. (2016)| 0.17 (0.05, 0.45) | 2.58     |
| Gau et al. (2020)   | 0.03 (0.01, 0.10) | 3.89     |
| Lin et al. (2019)   | 0.14 (0.03, 0.51) | 1.86     |
| Singh A. et al. (2018)| 0.03 (0.00, 0.13) | 4.17     |
| Singh T. et al. (2016)| 0.13 (0.02, 0.47) | 2.64     |
| Surendra et al. (2016)| 0.05 (0.01, 0.23) | 3.36     |
| Subtotal (I^2 = 22.9%, p = 0.25) | 0.07 (0.03, 0.13) | 25.67     |
| Insomnia            |             |          |
| Borgia et al. (2019)| 0.02 (0.00, 0.09) | 4.61     |
| He et al. (2017)    | 0.03 (0.01, 0.15) | 3.97     |
| Seo et al. (2020)   | 0.11 (0.02, 0.43) | 2.19     |
| Singh A. et al. (2018)| 0.10 (0.04, 0.24) | 4.17     |
| Singh T. et al. (2016)| 0.13 (0.02, 0.47) | 2.64     |
| Surendra et al. (2016)| 0.00 (0.00, 0.15) | 3.36     |
| Subtotal (I^2 = 26.2%, p = 0.24) | 0.03 (0.00, 0.08) | 20.34     |
| Nausea/Vomiting     |             |          |
| Borgia et al. (2019)| 0.14 (0.07, 0.25) | 4.61     |
| Debnath et al. (2019)| 0.22 (0.09, 0.45) | 3.15     |
| He et al. (2017)    | 0.39 (0.25, 0.56) | 3.97     |
| Singh A. et al. (2018)| 0.10 (0.04, 0.24) | 4.17     |
| Singh T. et al. (2016)| 0.13 (0.02, 0.47) | 2.64     |
| Surendra et al. (2018)| 0.00 (0.00, 0.15) | 3.36     |
| Subtotal (I^2 = 74.2%, p = 0.00) | 0.14 (0.04, 0.27) | 21.29     |
| Heterogeneity between groups: p = 0.147 | 0.10 (0.06, 0.14) | 100.00     |

Figure 4. Forest plot of included studies that reported adverse events. Individual and combined estimates of prevalence of each adverse event with 95% confidence intervals. ES effect size (prevalence).
effects model, because we assumed that the effects are heterogeneous due to differences in the study design, SOF dosage and combination drugs of each study. Studies were grouped by regimen dosage where possible, and a random effects meta-analysis was carried out in these sub-groups. We assessed the heterogeneity among studies and subgroups using the $I^2$ statistic. The Egger's test was used to explore publication bias and small study effects.

To evaluate the safety of the SOF-based regimens, we performed a random-effects meta-analysis for each adverse event reported in 3 or more studies, and estimated the pooled proportion of patients that reported each adverse event. A meta-regression analysis was also conducted to investigate the extent to which the differences in study characteristics were correlated with the between study heterogeneity. For our review, we used an intention to treat analysis. Patients lost to follow-up were considered as treatment failures.

Stata v15 (Stata Corporation, College Station, TX, USA) was used to perform the statistical analysis. The statistical significance threshold was set at 0.05.

Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Received: 25 January 2020; Accepted: 10 August 2020
Published online: 31 August 2020

References
1. Nguyen, D. B., Bixler, D. & Patel, P. R. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin. Dial. 32, 127–134. https://doi.org/10.1111/sdi.12761 (2019).
2. Jadoul, M. et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 95, 939–947. https://doi.org/10.1016/j.kint.2018.11.038 (2019).
7. Gilead Sciences. Sofosbuvir—Full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/20467s002lbl.pdf. (2015).

8. Li, M., Chen, J., Fang, Z., Li, Y. & Lin, Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: A systematic review and meta-analysis. Virol. J. 16, 34. https://doi.org/10.1186/s12985-019-1140-x (2019).

9. Saxena, V.

10. Akhil, M. S.

11. Gaur, N. et al. Sofosbuvir–velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J. Clin. Exp. Hepatol. 10, 189–193. https://doi.org/10.1016/j.jchab.2019.10.004 (2020).

12. Seo, H. Y., Seo, M. S., Yoon, S. Y., Choi, J. W. & Ko, S. Y. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C genotype 2-infected patients on hemodialysis. Korean J. Intern. Med. 35, 599–565. https://doi.org/10.3904/kjm.2018.338 (2020).

13. Agarwal, S. K., Bagchi, S. & Yadav, R. K. Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen. J. Clin. Exp. Hepatol. 8, 73–76. https://doi.org/10.1016/j.jceh.2017.04.005 (2017).

14. Bhamidimarri, K. R. et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simprevir in treatment of Hepatitis C patients with end stage renal disease. J. Hepatol. 63, 765–767. https://doi.org/10.1001/jhep.2015.06.004 (2015).

15. Choudhary, N. S. et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J. Gas- troenterol. 36, 113–166. https://doi.org/10.4103/0971-4101.166017-0 (2017).

16. Desnoyer, A. et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C J. Hepatol. 65, 40–47. https://doi.org/10.1016/j.jhep.2016.02.044 (2016).

17. Gupta, A., Arora, P. & Jain, P. Sofosbuvir based regimen in management of hepatitis C for patients with end stage renal disease on haemodialysis: A single center experience from India. J. Clin. Exp. Hepatol. 8, 116–120. https://doi.org/10.1016/j.jceh.2017.10.001 (2018).

18. He, Y. L. et al. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol. Ther. 47, 526–532. https://doi.org/10.1111/apt.14429 (2018).

19. Mehta, R. et al. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis. Indian J. Gastroenterol. 37, 72–73. https://doi.org/10.1007/s11096-018-0483-1 (2018).

20. Singh, T. et al. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: A case series. Liver Int. 36, 802–806. https://doi.org/10.1111/liv.13078 (2016).

21. Surendra, M. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study. Hemodial. Int. 22, 217–221. https://doi.org/10.1002/hdi.12604 (2018).

22. Borgia, S. M. et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J. Hepatol. 71, 660–665. https://doi.org/10.1016/j.jhep.2019.05.028 (2019).

23. Cheema, S. U. R., Rehman, M. S., Hussain, G., Cheema, S. S. & Giliani, N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing haemodialysis: A prospective interventional clinical trial. BMC Nephrol. 20, 438. https://doi.org/10.1186/s12882-019-1631-4 (2019).

24. Deb Nath, P. et al. Combined NS5a & NS5b nucleotide inhibitor therapy for patients with chronic hepatitis C with stage 5 chronic kidney disease. J. Gastroenterol. 57, 39–44. https://doi.org/10.1007/s00535-020-02019-0 (2020).

25. Hussein, N. R., Saleema, Z. S. M. & Abd, Q. H. Direct acting antiviral treatment for patients with end-stage kidney disease with acute HCV infection. Mediterr. J. Hematol. Infect. Dis. 11, e2019004. https://doi.org/10.4084/MJHID.2019.043 (2019).

26. Lin, T. et al. Effect of hemodialysis on efficacy and pharmacokinetics of sofosbuvir coformulated with either daclatasvir or ledipasvir in patients with end-stage renal disease. Blood Purif. https://doi.org/10.1159/000499161 (2020).

27. Mandhawani, R. et al. Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterol. Hepatol. Bed Bench 13, 141–146 (2020).

28. Singh, N., Kumari, S., Kumar, P., De, A. & Singh, V. Sofosbuvir with NSSA inhibitors in hepatitis C virus infection with severe renal insufficiency. J. Viral. Hepat. 25, 1501–1506. https://doi.org/10.1111/jvh.12983 (2018).

29. Canonicco, P. G. et al. Effects of ribavirin on red blood cells. Toxicol. Appl. Pharmacol. 74, 155–162. https://doi.org/10.1016/0041-008X(84)90138-8 (1984).

30. Gilead Sciences. EPClUSA(Sofosbuvir and velpatasvir) tablets, for oral use: Prescribing information. https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_ps.pdf. (2019).

31. Dolatimehr, F. et al. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. Daru 25, 11. https://doi.org/10.1186/s40199-017-0177-x (2017).

32. Yang, H. J., Ryoo, J. Y. & Yoo, B. K. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of Hepatitis C virus infection. Int. J. Clin. Pharm. 37, 698–708. https://doi.org/10.1007/s11096-015-0144-a (2015).

33. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097 (2009).

34. Wells, G. et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses (Ottawa Hospital Research Institute, Ottawa, 2016).

35. Sirinimnon, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188 (1986).

36. Nyaga, V. N., Arbyn, M. & Aerts, M. Metaprop: A Stata command to perform meta-analysis of binomial data. Arch. Public Health 72, 23, https://doi.org/10.1186/s12992-020-3258-2 (2014).

37. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558. https://doi.org/10.1002/sim.1186 (2002).

38. Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R. & Rushton, L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 295, 676–680. https://doi.org/10.1001/jama.295.6.676 (2006).

39. Harbord, R. M. & Higgins, J. P. T. Meta-regression in Stata. Stata J. 8, 493–519 (2008).

40. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188 (1986).
Author contributions
E.D., M.K., K.B., P.M., D.S., E.M. and F.S. contributed to the study concept and design. E.D., M.K., K.B. and F.S. performed the literature search and data extraction. F.S. performed the statistical analyses. All authors were involved in data analyses or review, and manuscript preparation. F.S. is the guarantor and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding
This work has been supported by the National Institute of Allergy and Infectious Diseases (K24 AI1119158 [EMCD]). The funding sources for this study played no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review or approval of the manuscript.

Competing interests
PM has acted as a Consultant and Investigator for Gilead. ED, KB DS, MK, EM and FS declare no conflicts of interest.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-71205-5.

Correspondence and requests for materials should be addressed to F.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020